Beam Therapeutics Q2 Earnings: Loss Narrower Than Expected, Revenue Misses Mark

Beam Therapeutics reported a Q2 loss of $1.00 per share, narrower than the Zacks Consensus Estimate of a loss of $1.04. Total revenues were $8.5 million, falling short of the Zacks Consensus Estimate of $14 million. R&D expenses increased 17% YoY to $101.8 million, while G&A expenses decreased 9.1% YoY to $26.9 million. The company expects its existing cash balance to fund operating expenses into 2028.

Title: Beam Therapeutics Reports Q2 Loss Narrower Than Expected, Revenue Misses Mark

Beam Therapeutics Inc. (BEAM) reported a quarterly loss of $1.00 per share for the second quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of $1.04 per share. The company's total revenue for the quarter amounted to $8.5 million, falling short of the Zacks Consensus Estimate of $14 million. The research and development (R&D) expenses increased by 17% year-over-year (YoY) to $101.8 million, while general and administrative (G&A) expenses decreased by 9.1% YoY to $26.9 million. Beam Therapeutics expects its existing cash balance to fund operating expenses into 2028 [1].

The company's leading ex-vivo genome-editing candidate, BEAM-101, is currently in the phase I/II BEACON study for the treatment of adult patients with sickle cell disease (SCD). Enrollment in the study has been completed, and updated data is expected to be presented by the end of 2025. Additionally, BEAM-301 and BEAM-302 are being developed for treating glycogen storage disease type 1a (GSD1a) and alpha-1 antitrypsin deficiency (AATD), respectively. Positive initial safety and efficacy data from a phase I/II study evaluating BEAM-302 for AATD were announced in March, and the FDA granted an orphan drug designation to BEAM-101 for the treatment of SCD in June [2].

Despite the quarterly loss, shares of Beam Therapeutics have declined 24.6% so far this year against the industry's rise of 1.9%. The company's Zacks Rank currently stands at #4 (Sell), with better-ranked stocks in the biotech sector such as CorMedix (CRMD), Arvinas (ARVN), and Immunocore (IMCR) each carrying a Zacks Rank #1 (Strong Buy) [3].

References
[1] https://www.barchart.com/story/news/33930362/beam-s-q2-loss-narrower-than-expected-revenues-miss-mark
[2] https://finance.yahoo.com/news/beam-therapeutics-inc-beam-reports-121503263.html
[3] https://www.ainvest.com/news/beam-therapeutics-2025-q2-earnings-net-loss-widen-eps-improvement-2508/